Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2004

View Archived Issues

Enclomiphene increases testosterone in hypogonadal men

New photosensitizer isolated from plant extract by AIST scientists

Novel kappa opioid agonists developed at SSP

Roche researchers identify new uPA antagonists for use in cancer therapy

Merck scientists present new nonsteroidal glucocorticoid receptor modulators

Kyorin patent covers novel S1P receptor ligands and their use

New TARC and MDC regulators prepared and tested at Kyowa Hakko

Novel prostanoid DP antagonists under study at Taisho

Merck KGaA presents novel factor Xa and factor VIIa inhibitors

R&D highlights from the 4th Annual Biotech In Europe Investor Forum: Neovacs

New phase III study for Ushercell in HIV

Positive findings from pharmacokinetic study of lingual spray sumatriptan

Oxytrol launched in Canada

Canadian warning on Eprex use in cancer patients

New safety information regarding Permax

ThromboView cleared to enter phase II study

ViRexx to acquire AltaRex Medical

Conversion of Sanctura agreement

Patient dosing begins for oral forodesine hydrochloride in phase I study

Restructuring at CuraGen

NDA submission for indiplon immediate release

STTR grant to fund development of SP-04 for Alzheimer's

ReGen to acquire Guildford Clinical Pharmacology Unit

Pharmacokinetics and safety profile of bazedoxifene in Chinese women

Paroxetine controlled release reported to be safe and effective in fibromyalgia

DailyDrugNews.com now featuring links to related information in Prous Science Integrity

LFM-A13 effective in model of graft-versus-host disease

Erectile dysfunction treatment with tadalafil extensively studied

IL-8 inhibition with statins a possible therapy for endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...